Literature DB >> 21641490

Auditory impairment in infants at risk for bilirubin-induced neurologic dysfunction.

Steven M Shapiro1, Gerald R Popelka.   

Abstract

Classical and subtypes of kernicterus associated with bilirubin toxicity can be differentiated in part with physiological auditory measures that include auditory-evoked potentials and measures of cochlear integrity. The combination of these auditory measures suggests that bilirubin exposure results in auditory system damage initially at the level of the brainstem, progressing to the level of the VIII cranial nerve and then to greater neural centers. There is no evidence of neural damage at the level of the cochlea. Auditory neural damage from bilirubin toxicity ranges from neural timing deficits, including neural firing delays and dyssynchrony, to neural response reduction and even elimination of auditory neural responses. This condition is comprehensively described as auditory neuropathy spectrum disorder. Independent measures of cochlear function and auditory neural function up to the level of the brainstem can effectively diagnose auditory neural damage resulting from bilirubin neurotoxicity. Intervention, including cochlear implants can be effective.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21641490     DOI: 10.1053/j.semperi.2011.02.011

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  23 in total

Review 1.  Plasticity in the developing auditory cortex: evidence from children with sensorineural hearing loss and auditory neuropathy spectrum disorder.

Authors:  Garrett Cardon; Julia Campbell; Anu Sharma
Journal:  J Am Acad Audiol       Date:  2012-06       Impact factor: 1.664

2.  Frequency-following response among neonates with progressive moderate hyperbilirubinemia.

Authors:  Gabriella Musacchia; Jiong Hu; Vinod K Bhutani; Ronald J Wong; Mei-Ling Tong; Shuping Han; Nikolas H Blevins; Matthew B Fitzgerald
Journal:  J Perinatol       Date:  2019-07-01       Impact factor: 2.521

3.  Effect of Hyperbilirubinemia on Medial Olivocochlear System in Newborns.

Authors:  Burak Karabulut; Mehmet Sürmeli; Şenol Bozdağ; İldem Deveci; Rıza Doğan; Çağatay Oysu
Journal:  J Int Adv Otol       Date:  2019-08       Impact factor: 1.017

Review 4.  Monitoring neonates for ototoxicity.

Authors:  Angela C Garinis; Alison Kemph; Anne Marie Tharpe; Joern-Hendrik Weitkamp; Cynthia McEvoy; Peter S Steyger
Journal:  Int J Audiol       Date:  2017-06-22       Impact factor: 2.117

5.  Serum bilirubin and bilirubin/albumin ratio as predictors of bilirubin encephalopathy.

Authors:  Iman Iskander; Rasha Gamaleldin; Salma El Houchi; Amira El Shenawy; Iman Seoud; Nesrin El Gharbawi; Hazem Abou-Youssef; Aleksandr Aravkin; Richard P Wennberg
Journal:  Pediatrics       Date:  2014-10-20       Impact factor: 7.124

Review 6.  Bilirubin-Induced Audiologic Injury in Preterm Infants.

Authors:  Cristen Olds; John S Oghalai
Journal:  Clin Perinatol       Date:  2016-02-15       Impact factor: 3.430

Review 7.  Universal newborn hearing screening: methods and results, obstacles, and benefits.

Authors:  Katarzyna E Wroblewska-Seniuk; Piotr Dabrowski; Witold Szyfter; Jan Mazela
Journal:  Pediatr Res       Date:  2016-11-18       Impact factor: 3.756

Review 8.  Audiologic impairment associated with bilirubin-induced neurologic damage.

Authors:  Cristen Olds; John S Oghalai
Journal:  Semin Fetal Neonatal Med       Date:  2015-01-07       Impact factor: 3.926

9.  Relationship between behavioral hearing thresholds and estimated auditory steady-state response thresholds in children with a history of neonatal hyperbilirubinemia.

Authors:  Rasool Panahi; Zahra Jafari; Sara Hasani
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-10-06       Impact factor: 2.503

Review 10.  Review of bilirubin neurotoxicity II: preventing and treating acute bilirubin encephalopathy and kernicterus spectrum disorders.

Authors:  Steven M Shapiro; Sean M Riordan
Journal:  Pediatr Res       Date:  2019-10-03       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.